Three patients received mTOR inhibitors as follows: patient 5 for 32 months, with estimated glomerular filtration rate declining from 86 to 58; patient 6 for 6 months, discontinued because of recurrent bronchitis; and patient 7 for AMLs with sirolimus, progressing to end-stage kidney disease 5 years later (Supplementary Table S3). This evidence concerns the gene MTOR and bronchial disorder.